Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares

Carina Stanton  |  April 21, 2020

ATLANTA—People with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) have recurring joint inflammation with a strong tendency to flare. Past research led by Margaret Chang, MD, PhD, a pediatric rheumatologist in the Division of Immunology at Boston Children’s Hospital, used a novel murine model to identify a population of memory T cells that persist in the synovium with a distinct resident memory T cell phenotype in recurrent, joint-specific inflammation.1

Last fall at the 2019 ACR/ARP Annual Meeting, Dr. Chang and her colleagues presented their latest findings on these cells as a potential target to reduce arthritic flare.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Targeting Flares
Resident memory T cells are site-specific memory T cells that reside long term in peripheral tissues as a defense against pathogens. However, these cells can also cause recurrent inflammation locally. Certain rheumatologic diseases, such as RA and JIA, are characterized by recurrent joint inflammation that exhibits a strong tendency to flare at the same sites.

To understand how resident memory T cells may be manipulated for therapeutic aims, Dr. Chang and colleagues used a murine model of site-specific recurrent synovitis.1 They used intra-articular injection of adeno-associated virus to label synovial T cells in fluorescent reporter mice, tracking the site-specific persistence of resident memory T cells. They used a single intra-articular injection of diphtheria toxin in mice with Lck-inducible diphtheria toxin receptors to locally deplete synovial T cells prior to triggering an arthritis flare. Depletion of synovial T-cells made the joint relatively resistant to developing inflammatory arthritis. This approach demonstrated the contribution of synovial resident memory T cells to the flare response.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The results showed synovial resident memory T cells persist in previously inflamed joints eight months after remission and retain their capacity to trigger site-specific flare. Adeno-associated, virus-labeled resident memory T cells present in the synovium during remission did not migrate to the contralateral joint. These cells enabled joint inflammation by recruiting effector lymphocytes to the joint, and correspondingly, the localized depletion of resident memory T cells strongly blunted the capacity to trigger flare arthritis.

Managing Flares Without Immunosuppression
Dr. Chang says the hope is to target resident memory T cells in the joints experiencing flares and deplete the cells locally.

“Many of our patients with RA and JIA have to remain on systemic therapies to stay in remission. By locally depleting these [resident memory T cells], we theorize that sustained disease control or even an effective cure could be achieved without the need for systemic immunosuppression,” she says.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:2019 ACR/ARP Annual MeetingFlaresjointjuvenile idiopathic arthritis (JIA)Rheumatoid Arthritis (RA)

Related Articles

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis

    May 5, 2022

    The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…

    Patient-Centered Care Model for RA Flares Could Improve Self-Management of Symptoms

    December 16, 2015

    A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences